Category: Press Release

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 8, 2017– AVEO Oncology (NASDAQ: AVEO) today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. patent application number 14/653,684, entitled “notch binding agents and antagonists and methods of use thereof.” Allowed under the application are composition of matter and method of use

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 4, 2017– AVEO Oncology (NASDAQ:AVEO) today reported financial results for the first quarter ended March 31, 2017, and provided a business update. “We strengthened our balance sheet in the first quarter through an underwritten public offering, giving us the resources to potentially fund operations through the readout of our pivotal, Phase 3 TIVO-3 study

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Apr. 20, 2017– AVEO Oncology (NASDAQ:AVEO) today announced that poster presentations for three clinical studies will be presented at the upcoming 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2-6, 2017. Among these is a Trials in Progress presentation highlighting the ongoing Phase 3, randomized, controlled, multi-center, open-label TIVO-3 study comparing tivozanib, the Company’s potent, selective,

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Apr. 13, 2017– AVEO Oncology (NASDAQ: AVEO) today announced that its European licensee for tivozanib, EUSA Pharma, has submitted responses to the European Medicines Agency (EMA) Day 180 List of Outstanding Issues (LOI) related to the Marketing Authorization Application (MAA) for tivozanib as a first-line treatment for renal cell carcinoma. With submission of the response complete,

Download PDF Company Provides Updated Financial Guidance CAMBRIDGE, Mass.–(BUSINESS WIRE)–Apr. 3, 2017– AVEO Oncology (NASDAQ:AVEO) today announced receipt of a $500,000 milestone payment from CANbridge Life Sciences Ltd., a biopharmaceutical company focused on developing western drug candidates in China and North Asia, related to a technology transfer milestone for AV-203, AVEO’s clinical-stage ErbB3 (HER3) inhibitory antibody candidate. AV-203 has demonstrated preclinical activity in

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Mar. 31, 2017– AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) today announced the closing of its previously announced underwritten public offering of 34,500,000 shares of common stock, including the exercise in full by the underwriter of its option to purchase 4,500,000 shares at the public offering price of $0.50 per share. The exercise of the option increased the

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Mar. 28, 2017– AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Mar. 28, 2017– AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that it has priced an underwritten public offering of 30,000,000 shares of common stock at a price to the public of $0.50 per share, before underwriting discounts, which would result in aggregate gross proceeds of approximately $15 million. All of the shares in the offering are to

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Mar. 22, 2017– AVEO Oncology (NASDAQ:AVEO) today announced that the first patient has been dosed in the Phase 1/2 AVEO-sponsored TiNivo trial evaluating tivozanib in combination with Bristol-Myers Squibb’s anti-PD-1 therapy, Opdivo® (nivolumab), in advanced renal cell carcinoma (RCC). The study, which will be led by the Institut Gustave Roussy in Paris, is under the

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Mar. 22, 2017– AVEO Oncology (NASDAQ:AVEO) today reported financial results for the full year ended December 31, 2016 and provided a business update. “TIVO-3, our lead clinical program designed to serve as the basis for a potential U.S. registration for tivozanib as a first- and third-line treatment for renal cell cancer, continues to enroll